HepaPredict AB was founded in 2016 as a private spin-off from Karolinska Institutet, Stockholm, Sweden. We are a contract research organization (CRO) specializing in drug metabolism, toxicity and drug development for liver disease, such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), fibrosis and cholestasis. Our services are based around a well established 3D primary human liver spheroid culture platform developed at Karolinska Institutet by our founders. We offer in-house evaluations of drug metabolism, pharmacokinetic properties and safety as well as drug target validations. The platform is the most extensively characterized 3D spheroid system available, offering unmatched predictive accuracy. The key attributes are: • Physiologically replicative in vitro system with close resemblance to human liver on transcriptomic, proteomic and metabolomic level. • Optimized to support co-cultures with non-parenchymal cells, such as Kupffer, biliary, and Stellate cells. • Functionally stable and suitable for chronic applications, thus allowing to assess long-term toxicity, pharmacokinetics and chronic drug response, not supported by conventional in vitro systems. • Easy manipulation of gene expression through knockdown or knockin techniques. • Emulation of human inter-individual variability in an in vitro setting. • High-throughput compatibility and scalability allows screening of hundreds of conditions and/or drug candidates with multiple replicates, adding to statistical power. • Controlled, chemically defined experimental conditions ensure maximal reproducibility. • Direct translation of findings to patients by using patient derived cells instead of cell lines or animal models.